MX2017014056A - Construcciones dirigidas a complejos de peptido e7 del subtipo 16 del virus de papiloma humano (hpv16-e7)/complejo principal de histocompatibilidad (mhc) y sus usos. - Google Patents
Construcciones dirigidas a complejos de peptido e7 del subtipo 16 del virus de papiloma humano (hpv16-e7)/complejo principal de histocompatibilidad (mhc) y sus usos.Info
- Publication number
- MX2017014056A MX2017014056A MX2017014056A MX2017014056A MX2017014056A MX 2017014056 A MX2017014056 A MX 2017014056A MX 2017014056 A MX2017014056 A MX 2017014056A MX 2017014056 A MX2017014056 A MX 2017014056A MX 2017014056 A MX2017014056 A MX 2017014056A
- Authority
- MX
- Mexico
- Prior art keywords
- peptide
- mhc complexes
- constructs targeting
- hpv16
- constructs
- Prior art date
Links
- 101000767631 Human papillomavirus type 16 Protein E7 Proteins 0.000 title abstract 2
- 230000008685 targeting Effects 0.000 title 1
- 102000043129 MHC class I family Human genes 0.000 abstract 1
- 108091054437 MHC class I family Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/464838—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
- C07K16/084—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/59—Reproductive system, e.g. uterus, ovaries, cervix or testes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
Abstract
La presente solicitud proporciona construcciones que comprenden una porción de anticuerpo que específicamente se une a un complejo que comprende un péptido HPVI6-E7 y una proteína MHC de clase I. También se proporcionan métodos para hacer y utilizar estas construcciones.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562158735P | 2015-05-08 | 2015-05-08 | |
US201562197480P | 2015-07-27 | 2015-07-27 | |
PCT/US2016/031364 WO2016182957A1 (en) | 2015-05-08 | 2016-05-06 | Constructs targeting hpv16-e7 peptide/mhc complexes and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2017014056A true MX2017014056A (es) | 2018-04-10 |
Family
ID=57249446
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2017014056A MX2017014056A (es) | 2015-05-08 | 2016-05-06 | Construcciones dirigidas a complejos de peptido e7 del subtipo 16 del virus de papiloma humano (hpv16-e7)/complejo principal de histocompatibilidad (mhc) y sus usos. |
Country Status (12)
Country | Link |
---|---|
EP (1) | EP3294328A1 (es) |
JP (1) | JP2018516879A (es) |
KR (1) | KR20170141256A (es) |
CN (1) | CN107847570A (es) |
AU (1) | AU2016261356A1 (es) |
CA (1) | CA2988397A1 (es) |
IL (1) | IL255228A0 (es) |
MX (1) | MX2017014056A (es) |
RU (1) | RU2017142716A (es) |
SG (1) | SG11201708674XA (es) |
TW (1) | TW201713695A (es) |
WO (1) | WO2016182957A1 (es) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2016342041B2 (en) | 2015-10-23 | 2021-12-02 | Eureka Therapeutics, Inc. | Antibody/T-cell receptor chimeric constructs and uses thereof |
CN110741016A (zh) | 2017-04-26 | 2020-01-31 | 优瑞科生物技术公司 | 嵌合抗体/t-细胞受体构筑体及其用途 |
EA202090149A1 (ru) * | 2017-06-28 | 2020-05-31 | Ридженерон Фармасьютикалз, Инк. | Антигенсвязывающие белки против вируса папилломы человека (hpv) и способы их применения |
EP4215543A3 (en) | 2017-10-03 | 2023-10-11 | Juno Therapeutics, Inc. | Hpv-specific binding molecules |
KR102281405B1 (ko) * | 2017-10-20 | 2021-07-26 | 주식회사 파멥신 | 항-vista 항체 및 이의 용도 |
CN110776562B (zh) * | 2018-07-30 | 2022-06-17 | 香雪生命科学技术(广东)有限公司 | 一种识别afp抗原的t细胞受体 |
CN113045655A (zh) * | 2019-12-27 | 2021-06-29 | 高诚生物医药(香港)有限公司 | 抗ox40抗体及其用途 |
EP4101866A4 (en) | 2020-02-06 | 2024-04-24 | Univ Ajou Ind Academic Coop Found | FUSION ANTIBODY ALLOWING PRESENTATION OF A T CELL ANTIGEN EPITOPE DERIVED FROM AN ANTIGEN OR PEPTIDE CONTAINING IT ON A CELL SURFACE, AND COMPOSITION COMPRISING SAME |
US11168128B2 (en) | 2020-02-26 | 2021-11-09 | Vir Biotechnology, Inc. | Antibodies against SARS-CoV-2 and methods of using the same |
CN113321726A (zh) * | 2020-02-28 | 2021-08-31 | 香雪生命科学技术(广东)有限公司 | 一种识别hpv的t细胞受体 |
CN113801217A (zh) * | 2020-06-17 | 2021-12-17 | 香雪生命科学技术(广东)有限公司 | 一种识别hpv抗原的高亲和力t细胞受体 |
US11883432B2 (en) | 2020-12-18 | 2024-01-30 | Century Therapeutics, Inc. | Chimeric antigen receptor system with adaptable receptor specificity |
CN113637690A (zh) * | 2021-08-18 | 2021-11-12 | 武汉华美生物工程有限公司 | 一种人***瘤病毒hpv16型e7活性蛋白的制备方法及应用 |
WO2023133193A1 (en) * | 2022-01-05 | 2023-07-13 | Memorial Sloan-Kettering Cancer Center | Anti-hpv antibodies and uses thereof |
WO2024050399A1 (en) * | 2022-09-01 | 2024-03-07 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Single domain antibodies targeting hpv e6/e7 oncogenic peptide/mhc complexes |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090304679A1 (en) * | 2004-05-27 | 2009-12-10 | Weidanz Jon A | Antibodies as T cell receptor mimics, methods of production and uses thereof |
-
2016
- 2016-05-06 CA CA2988397A patent/CA2988397A1/en not_active Abandoned
- 2016-05-06 EP EP16793285.4A patent/EP3294328A1/en not_active Withdrawn
- 2016-05-06 CN CN201680039553.5A patent/CN107847570A/zh active Pending
- 2016-05-06 RU RU2017142716A patent/RU2017142716A/ru not_active Application Discontinuation
- 2016-05-06 AU AU2016261356A patent/AU2016261356A1/en not_active Abandoned
- 2016-05-06 MX MX2017014056A patent/MX2017014056A/es unknown
- 2016-05-06 SG SG11201708674XA patent/SG11201708674XA/en unknown
- 2016-05-06 KR KR1020177035048A patent/KR20170141256A/ko unknown
- 2016-05-06 WO PCT/US2016/031364 patent/WO2016182957A1/en active Application Filing
- 2016-05-06 JP JP2017557069A patent/JP2018516879A/ja active Pending
- 2016-05-09 TW TW105114353A patent/TW201713695A/zh unknown
-
2017
- 2017-10-24 IL IL255228A patent/IL255228A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
RU2017142716A (ru) | 2019-06-10 |
WO2016182957A1 (en) | 2016-11-17 |
KR20170141256A (ko) | 2017-12-22 |
TW201713695A (zh) | 2017-04-16 |
JP2018516879A (ja) | 2018-06-28 |
EP3294328A1 (en) | 2018-03-21 |
CA2988397A1 (en) | 2016-11-17 |
IL255228A0 (en) | 2017-12-31 |
CN107847570A (zh) | 2018-03-27 |
SG11201708674XA (en) | 2017-11-29 |
AU2016261356A1 (en) | 2018-01-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12017502390A1 (en) | Constructs targeting ny-eso-1 peptide/mhc complexes and uses thereof | |
MX2017012352A (es) | Construccion dirigida a complejos de peptido de alfa-fetoproteina/complejo principal de histocompatibilidad (afp/cph) y usos de los mismos. | |
MX2017014056A (es) | Construcciones dirigidas a complejos de peptido e7 del subtipo 16 del virus de papiloma humano (hpv16-e7)/complejo principal de histocompatibilidad (mhc) y sus usos. | |
CY1123163T1 (el) | Αντισωματα που δεσμευουν beta klotho επικρατεια 2 και μεθοδοι χρησης αυτων | |
CY1123977T1 (el) | Anti-pd-1 και anti-lag3 αντισωματα για την θεραπεια του καρκινου | |
CY1124106T1 (el) | Συνθεσεις μεταφορεα-αντισωματος και μεθοδοι παρασκευης και χρησης αυτων | |
CY1125260T1 (el) | Παραγοντες δεσμευσης tigit και χρησεις τους | |
PH12018502478A1 (en) | Bispecific binding proteins binding an immunomodulatory protein and a tumor antigen | |
PH12018500380A1 (en) | Anti-dll3 antibody drug conjugates and methods of use | |
ECSP18082207A (es) | Neoantígenos y métodos de su uso | |
SA517381703B1 (ar) | C10orf54 - أجسام مضادة لـ واستخداماتها | |
PH12018500159A1 (en) | Constructs targeting psa peptide/mhc complexes and uses thereof | |
MX2015012122A (es) | Conjugados de anticuerpo-farmaco y los anticuerpos correspondientes. | |
PH12017500002A1 (en) | Anti-cdh6 antibody drug conjugates | |
EA201891709A1 (ru) | Антигенсвязывающие белки, связывающие pd-l1 | |
PH12016502061A1 (en) | Novel antii-rnf43 antibodies and methods of use | |
PH12017500406A1 (en) | Novel anti-mfi2 antibodies and methods of use | |
MX2018006249A (es) | Nuevos anticuerpos anti-emr2 y metodos de uso. | |
MX2019004690A (es) | Constructos de anticuerpos. | |
PH12019500802A1 (en) | Antibodies that bind zika virus envelope protein and uses thereof | |
MX2018007817A (es) | Nuevos anticuerpos anti-mmp16 y metodos para su uso. | |
MX2018013484A (es) | Nuevos anticuerpos anti-tnfrsf21 y modos de uso. | |
MX2018007818A (es) | Anticuerpos dirigidos contra upk1b novedosos y metodos para su uso. | |
JO3545B1 (ar) | تركيبات الناقل-الجسم المضاد وطرق صناعتها واستخدامها |